Bridgewater Chapter Upcoming Events Join PCCI

Monday, April 13, 2009

Embassy Suites, Chesterbrook, Pennsylvania (directions)


JDP Therapeutics Inc.

A Biopharmaceutical Company

Presenter: Jie Du, PhD, President and CEO of JDP Therapeutics



JDP Therapeutics Inc. (JDP) is a biopharmaceutical company focusing on innovation and development of allergy therapies.


Approximately 1 in 5 people in the USA suffer from allergies and the number is increasing every year. Antihistamines, also known as H1-receptor antagonists, are the first line of treatment for most forms of allergies. The American Academy of Allergy, Asthma and Immunology (AAAAI) estimates that seasonal allergies cause over 8.2 million days of restricted activity, 3.8 million lost school and work days and 16.7 million medical office visits. Spending on prescription allergy remedies accounted for more than $6 billion per year in the US alone. Yet, there remains a large unmet medical need for an allergy remedy that is effective, safe, and, importantly, without sedation. AAAAI’s survey in 2005 found that 47% of patients are taking multiple Rx allergy medications… because “they are increasingly unsatisfied with their allergy medications”.


Diphenhydramine (Benadryl®), a first generation antihistamine, has been considered by most health care providers as the gold standard of allergy treatment for both hives and overall allergy symptoms. But its severely sedating side effect has prevented its wide use. The company’s lead compound, JDP-203, is a new chemical entity with similar effectiveness as diphenhydramine. In animal studies, JDP-203 has shown a similar antihistamine effect as diphenhydramine, but without causing sedation, heart QT prolongation, or antimuscarinic side effects. The mice model showed a significantly reduced sedation of JDP-203 in comparison to diphenhydramine. JDP is in-licensing this technology from the patent holder who owns the intellectual properties and has conducted significant amount of pre-clinical animal studies.


JDP is currently raising $1 million in seed capital to conduct CMC and prepare for the pre-IND meeting with FDA on JDP-203. The regulatory filing will be supported by ICON Solutions in North Wales PA. With the CEO’s extensive experience in clinical affairs, the Company is to execute its clinical program in connection with its regulatory filing in a cost efficient and time efficient manner. The company plans to exit during the phase II clinical trial of JDP-203.



3 Major Issues


  1. Currently we only have data in animal models. How much pre-clinical data is needed to convince a potential investor to move forward with an investment? Do we have enough pre-clinical data to support a potential investment? What are the main challenges (from an investor perspective) associated with bringing a new drug into a therapeutically crowded area? What would be the best way to distinguish JDP-203 from other antihistamine drugs (Allegra, Xyzal, & Clarinex)?

  2. JDP is negotiating an exclusive license to the IP from the patent holder. What are reasonable licensing terms that would benefit the company and the patent owner, and also enable the company to raise funds? What kind of negotiation strategies should we consider? What is the best type of licensing deal structure for this type of product?

  3. From regulatory point of view, what will be the main challenges or hurdles to consider of entering a highly profitable but low disease severity therapeutic area? How will the FDA react to this drug?





6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Jie Du, PhD, President and CEO of JDP Therapeutics will deliver the Company's "Elevator" Pitch to the Group

8:15 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests



<Top of the page>





Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


None available at this time


None available at this time


None available at this time

Contact Info:

Jie Du, Ph.D.
President & CEO
JDP Therapeutics, Inc.
823 Jays Drive
Lansdale, PA 19446

Tel: 215-661-8557
Cell: 267-218-4185



List of Attendees

Amoriello Stephen
Becker Michael (panelist )
Behrens Carl
Bell Caroline
Benn Vincent
Bianchi John
Blaxland Chris
Clementi Bill (panelist)
Conley Aime
Dally Janet
Davis Cynthia
Derrico Ellen
Essig Richard
Giovenella Al
Hand, Jim
Harris Dianne (panelist)
Hartupee Dale
Hausner Brian
Hausner Brian
Hesson David
Hughes, Glenn
Hutchinson Duffy
Johnson Joe
Kentner Lee
Jie Du (presenter)
Lindner Marie
Macdonald Loch Edge Ther.
Martini Jeff
Maurer Chris
Milby Randy
Moore Bill
Morris Susan
Patterson Joe
Pelura Tim
Pourkavoos, Nazaneen
Rodwell John
Rothnan Ronald
Schina Michael
Settineri, Frank
Siegel Marvin
Siegel Scott
Simon Paul
Skerrett Don
Soranno Carl Edge Ther.
Stern Larry
Temeles Gretchen
Thompson Tom
Thompson Sage
Van der Kam Peter
Warshafsky Jordan
Wasserbly, Pamela
Weinstein Josh
Wells Beth
Zack Joe
Zindulis Joe
Zodda Deni






Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc